Fairvalue-Calculator Fairvalue-Calculator
EN DE

Contineum Therapeutics, Inc (CTNM) Fair Value & Analysis

Healthcare · US · Market cap $446M

Price$11.91
Fair Value$7.71
Upside-35.3%
Quality95/100
Evidence: Low Range $5.09 – $9.64

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Contineum Therapeutics, Inc (CTNM) currently trades at $11.91, while our model-based Fair Value estimate is $7.71 — implying the stock looks roughly 35.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Contineum Therapeutics, Inc (CTNM) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $7.71 versus a price of $11.91 — about −35% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CTNM?
Our 21-model fair value for Contineum Therapeutics, Inc is $7.71 (as of Jun 25, 2026), built from audited fundamentals. The current price is $11.91.
What is the quality score of CTNM?
Contineum Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.